SRX Global And CERO 1236, A Wholly-Owned SPV, Enter Into Definitive Agreement To Acquire CERo Therapeutics, An Innovative Cellular Immunotherapy Company Developing CER 1236 For Hematologic Malignancies >SRXH

Dow Jones2026/10/07 19:00

By:Dow Jones

SRX Global And CERO 1236, A Wholly-Owned SPV, Enter Into Definitive Agreement To Acquire CERo Therapeutics, An Innovative Cellular Immunotherapy Company Developing CER 1236 For Hematologic Malignancies >SRXH

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

IHeartMedia 3Q Rev $1.03B >IHRT

Dow Jones•2026/11/09 21:05

-- Earnings Flash (MARA) MARA Posts Q3 Revenue $164.2M, vs. FactSet Est of a $183.2M

MT newswire•2026/11/09 20:40

-- GUIDANCE: (ZETA) Zeta Global Holdings Corp. Expects Q4 Revenue Range $521.0M - $525.0M

MT newswire•2026/11/09 20:07

-- Earnings Flash (SEPN) Septerna, Inc. Reports Q3 Revenue $18.9M, vs. FactSet Est of $20.8M

MT newswire•2026/11/09 20:02